ARRDC3 and lymphoma: While baseline Arrdc3 expression levels were similar between untreated control and Trp53KOEμ-Myc lymphoma cells, there was a marked increase in Arrdc3 expression after treatment with nutlin-3a in the NTsgRNA Eμ-Myc lymphoma cells (~7–17-fold induction over 6–24 h) and treatment with etoposide (~5–10-fold induction over 6–24 h), but no such increase was seen in the Trp53KOEμ-Myc lymphoma cells (Figs. 2A, S3).